Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised …
Background Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with
activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or …
activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or …
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised …
Background Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown
superior efficacy to chlorambucil monotherapy and are standard first-line treatments in …
superior efficacy to chlorambucil monotherapy and are standard first-line treatments in …
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study
MS Davids, BL Lampson, S Tyekucheva… - The Lancet …, 2021 - thelancet.com
Background Both continuous therapy with acalabrutinib and fixed-duration therapy with
venetoclax–obinutuzumab are effective for previously untreated chronic lymphocytic …
venetoclax–obinutuzumab are effective for previously untreated chronic lymphocytic …
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in …
Bruton tyrosine kinase (BTK) inhibitors have improved chronic lymphocytic leukemia (CLL)
outcomes and offer a chemotherapyfree option [1]. The BTK inhibitor ibrutinib, alone or with …
outcomes and offer a chemotherapyfree option [1]. The BTK inhibitor ibrutinib, alone or with …
Acalabrutinib±obinutuzumab vs obinutuzumab+ chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of elevate-TN
Background: Previous reports of ELEVATE-TN (NCT02475681) at median follow-up of up to
58.2 months (mo) demonstrated superior efficacy of acalabrutinib (A)±obinutuzumab (O) …
58.2 months (mo) demonstrated superior efficacy of acalabrutinib (A)±obinutuzumab (O) …
[HTML][HTML] First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized …
C Moreno, R Greil, F Demirkan, A Tedeschi, B Anz… - …, 2022 - ncbi.nlm.nih.gov
Abstract iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus
obinutuzumab (n= 113) versus chlorambucil plus obinutuzumab (n= 116) as first-line …
obinutuzumab (n= 113) versus chlorambucil plus obinutuzumab (n= 116) as first-line …
[HTML][HTML] ELEVATE TN: phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive …
JP Sharman, V Banerji, LM Fogliatto, Y Herishanu… - Blood, 2019 - Elsevier
Background: Acalabrutinib is a highly selective, covalent irreversible Bruton tyrosine kinase
inhibitor with minimal activity against other kinases. Acalabrutinib has demonstrated durable …
inhibitor with minimal activity against other kinases. Acalabrutinib has demonstrated durable …
Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial
PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We …
ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic …
P Ghia, A Pluta, M Wach, D Lysak, T Kozak… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was
evaluated in this global, multicenter, randomized, open-label, phase III study in patients with …
evaluated in this global, multicenter, randomized, open-label, phase III study in patients with …
Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a …
CU Niemann, T Munir, C Moreno, C Owen… - The Lancet …, 2023 - thelancet.com
Background In the GLOW study, fixed-duration ibrutinib–venetoclax showed superior
progression-free survival versus chlorambucil–obinutuzumab in patients with previously …
progression-free survival versus chlorambucil–obinutuzumab in patients with previously …